Biocon Limited
BIOCON
Rangering i aksjer
#3400
Biocon Limited functions as a biopharmaceutical firm, engaged in the production... Biocon Limited functions as a biopharmaceutical firm, engaged in the production of pharmaceutical, medicinal chemical, and plant-derived products. Its business activities are organized into distinct segments: Generics, Novel Biologics, Biosimilars, and Research Services. The company dedicates its efforts to crucial therapeutic domains, including diabetes, oncology, immunology, ophthalmology, and bone health disorders. Furthermore, Biocon provides comprehensive services encompassing the discovery, development, and manufacturing of both small and large molecules. With a wide international presence, it caters to customers in roughly 120 nations. Headquartered in Bengaluru, India, Biocon Limited commenced operations in 1978.
Aksjekurs
$3.78
Markedsverdi
$5.16B
Endring (1 dag)
0.75%
Endring (1 år)
-9.11%
Land
IN
Handel Biocon Limited (BIOCON)
Kategori
Healthcare
Inntekter for Biocon Limited (BIOCON)
Inntekter i Jun 2026 TTM: $1.91B
Ifølge de nyeste økonomiske rapportene til Biocon Limited er selskapets nåværende inntekter (TTM) $1.91B. I 2024 hadde selskapet inntekter på $1.77B en økning sammenlignet med inntektene i 2023, som var $1.36B. Inntektene er det totale beløpet et selskap genererer fra salg av varer eller tjenester. I motsetning til fortjeneste trekkes ingen kostnader fra.
Inntektshistorikk for Biocon Limited fra 2004 til 2026
Inntekter ved slutten av hvert år
| År | Inntekter | Endre |
|---|---|---|
| 2026 (TTM) | $1.91B | 6.92% |
| 2025 | $1.78B | 0.84% |
| 2024 | $1.77B | 30.15% |
| 2023 | $1.36B | 26.12% |
| 2022 | $1.08B | 10.49% |
| 2021 | $975.78M | 16.67% |
| 2020 | $836.33M | 5.32% |
| 2019 | $794.12M | 25.39% |
| 2018 | $633.30M | 5.55% |
| 2017 | $600.02M | 18.75% |
| 2016 | $505.27M | 2.04% |
| 2015 | $495.17M | -3.94% |
| 2014 | $515.48M | 12.70% |
| 2013 | $457.40M | 13.20% |
| 2012 | $404.08M | -21.72% |
| 2011 | $516.22M | 13.85% |
| 2010 | $453.41M | 67.79% |
| 2009 | $270.22M | 29.75% |
| 2008 | $208.27M | 9.73% |
| 2007 | $189.80M | 22.96% |
| 2006 | $154.36M | 4.28% |
| 2005 | $148.03M | 28.03% |
| 2004 | $115.62M | 0.00% |
Inntekter for lignende selskaper eller konkurrenter
| Selskap | Inntekter | Forskjell i inntekter | Land |
|---|---|---|---|
| $12.62B | 561.69% |
US
|
|
| $2.23B | 16.78% |
US
|
|
| $15.74B | 725.22% |
AU
|
|
| - | - |
CH
|
|
| $6.02B | 215.60% |
NL
|
